Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-γδ T Cells in Relapsed/Refractory Autoimmune Nephropathy
NCT07535138Phase 1Not yet recruiting
- Sponsor
- Air Force Medical University
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-γδ T cell (Air Force Military Medical University) in membranous nephropathy (MN), lupus nephritis (LN) and IgA nephropathy (IgAN), sponsored by Air Force Medical University. Primary endpoints: Incidence of Dose-Limiting Toxicities and Incidence of Adverse Events. Planned start May 2026; status: not yet recruiting.
02
Drugs
CD19 CAR-γδ T cell (Air Force Military Medical University)
03
Conditions
membranous nephropathy (MN)lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07535138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535138.